Two global Phase 3 trials in adults with CLL demonstrated superior efficacy for BRUKINSA in first line and relapsed/refractory settings
TORONTO, May 30, 2023 /CNW/ – BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, announced today that (PR) BRUKINSA® (zanubrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, has been granted a Notice of Compliance from Health Canada for the treatment of adult patients with chronic lymphocytic leukemia (CLL).
lymphocytic leukemia (CLL). (CNW Group/BeiGene Canada)” data-facebook-share-text=”BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, has been granted a Notice of Compliance from Health Canada for the treatment of adult patients with chronic lymphocytic leukemia (CLL). (CNW Group/BeiGene Canada)” data-linkedin-text=”BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, has been granted a Notice of Compliance from Health Canada for the treatment of adult patients with chronic lymphocytic leukemia (CLL). (CNW Group/BeiGene Canada)” data-download-url=”https://mma.prnewswire.com/media/2087760/BeiGene_Canada_Health_Canada_Approves_PR__BRUKINSA___zanubrutini.jpg?p=publish” data-pinterest-text=”BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase (BTK)